Video content material above is prompted by the next questions:
- Please briefly talk about the most recent outcomes from the SEQUOIA Arm D trial, evaluating zanubrutinib plus venetoclax in treatment-naïve sufferers with CLL and del(17p) and/or TP53 mutations.
- How does the efficacy of zanubrutinib + venetoclax examine to SOCs in high-risk sufferers with del(17p) and/or TP53 mutations in CLL/SLL?
